Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Strategy Firm Acquires $1 Billion in Bitcoin Through Preferred Stock Offering

In a notable move within the cryptocurrency market, Strategy, a prominent entity known for its aggressive Bitcoin acquisition strategy, has secured an additional 13,927 Bitcoin. This substantial purchase, valued at around $1 billion, was uniquely financed through the sale of the company's preferred stock, known as Stretch. This latest transaction underscores Strategy's innovative approach to expanding its digital asset portfolio without utilizing its existing cash reserves, demonstrating a continued belief in the long-term value of Bitcoin despite recent market fluctuations.
Led by Executive Chairman Michael Saylor, Strategy executed this significant acquisition last week. The transaction saw Bitcoin acquired at an average price of $71,902 per digital coin. This method of funding, entirely through preferred stock, marks a distinct strategic choice, emphasizing the company's commitment to leveraging specialized financial instruments for its investment activities.
The preferred stock, Stretch, is specifically designed to offer high-yield monthly income to investors, maintaining a stable value of approximately $100. Its value is anchored by Strategy's extensive Bitcoin holdings. The monthly dividend yield for Stretch currently stands at 11.5%, a rate that is adjusted each month to ensure its share price remains close to the $100 mark. This structure provides a unique investment opportunity, intertwining traditional financial instruments with the volatile world of cryptocurrency.
This most recent purchase has augmented Strategy's total Bitcoin reserves to an impressive 780,897 coins. The cumulative acquisition cost for these holdings is approximately $59.02 billion, with an average cost basis of $75,577 per Bitcoin. The company's consistent buying activity has occurred even as Bitcoin's price has experienced a downturn over the past half-year, trading around $71,000 currently, a significant drop from its peak of $126,000 recorded last October. This persistence suggests a strong conviction in Bitcoin's future growth potential.
Despite the strategic accumulation of Bitcoin, Strategy's stock (MSTR) has seen a decline of 59% over the past twelve months, with shares trading at $128.64. This divergence between the company's asset acquisition strategy and its stock performance highlights the complex dynamics and investor sentiment surrounding firms deeply invested in the cryptocurrency sector. Nevertheless, Strategy's innovative financing and unwavering commitment to Bitcoin continue to position it as a key player in the digital asset landscape.

Pseudonym for Pete Adeney, a blogger who popularized extreme early retirement through frugality and investing.
Other Articles
GM's Resilience Amidst Automotive Industry Headwinds
Despite a challenging automotive market marked by declining sales, elevated interest rates, and geopolitical uncertainties, a leading analyst maintains a 'Buy' rating on General Motors (GM). The company's robust financial health, efficient cost structure, diversified product portfolio, and strategic capital returns position it favorably to navigate economic downturns, building on a strong performance in the previous year where it led US auto sales and achieved significant operating profits.
By Scott PapeIndex ETFs Versus Individual Stocks: A Prudent Investment Choice
Many investors often wonder whether to invest in individual stocks or broad market index ETFs. While individual stocks might offer a chance for significant gains, they come with higher risks. This article explores the advantages of investing in index ETFs like Vanguard S&P 500 ETF and Vanguard Total Stock Market ETF, highlighting how they offer diversified exposure and often outperform active managers. We delve into expert opinions, including Warren Buffett's advice, to provide a clear perspective on this investment dilemma.
By Mr. Money MustacheImmunityBio Reports Robust Q1 Preliminary Sales and ANKTIVA's Global Expansion
ImmunityBio Inc. (IBRX) announced strong preliminary Q1 2026 net product revenue of approximately $44.2 million, surpassing analyst expectations. The success is primarily attributed to its flagship therapy, ANKTIVA, which has secured regulatory approvals in five regions globally. The company also confirmed the completion of enrollment for a key clinical study and outlined measures to enhance regulatory compliance following recent communications with the FDA.
By Dave Ramsey